Key facts
- This page summarizes John A. Orwin's Form 4 filing for ANAPTYSBIO, INC (ANAB).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 Jan 2025, 17:29.
John A. Orwin - 07 Jan 2025 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)
- Reporting relationship
- Director
- Issuer ticker
- ANAB
- Reported as of
- 07 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Jan 2025, 17:29:38 UTC
- Prior SEC filing
- 17 Sep 2024
- Next SEC filing
- 16 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eric Loumeau, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John A. Orwin filed Form 4 for ANAPTYSBIO, INC (ANAB) on 07 Jan 2025.
Change
- Previous filing in this sequence was filed on 17 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANAB
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +16,510
- Change %
- Price
- $0.000000
- Shares after
- 16,510
- Date
- 07 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,510
- Exercise price
- $14.83
- Footnotes
- F1
ANAB
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +6,030
- Change %
- Price
- $0.000000
- Shares after
- 6,030
- Date
- 07 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,030
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The stock option vests as to 1/12 of the total shares monthly commencing on Februray 7, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Footnote F2
Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Footnote F3
The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.